Neopharm Group is a global player in the health care industry, with operations spanning research and development, manufacturing, marketing, sales, and distribution across 60 countries. Established in 1941, the company boasts a workforce of over 900 employees, generating annual revenues exceeding $US400 million. With its presence in Israel, Europe, the U.S., and the Middle East, Neopharm Group operates in three key areas: pharmaceuticals, consumer products, and medical devices. Under its umbrella, "Neopharm Israel" focuses on innovative health solutions in oncology, hematology, autoimmune and metabolic diseases, neurology, gastroenterology, and dermatology. Meanwhile, "Neovi," a Swiss-based biopharmaceutical company, specializes in novel antibody therapies in transplantation medicine, oncology, and immune disorders. "Eldan" provides advanced instruments and technologies in healthcare and life science, while "Neopharm consumer products" offers wellness and health care products in partnership with leading Consumer Healthcare companies. The group's subsidiaries also include "Promedico," offering logistics and supply chain management services, "Neopharm Cure," specializing in the preparation and delivery of medicinal treatments, and "DPL," focusing on the production and export of advanced absorbent products like disposable diapers, wipes, and sanitary napkins. The company's commitment to humanity, professionalism, and innovation is evident, and potential job opportunities can be explored on their website. Neopharm Group's diverse portfolio and international presence make it an intriguing prospect for investors looking to tap into the ever-expanding health and wellness industry.
There is no investment information
No recent news or press coverage available for Neopharm Group.